Journal of Immunotherapy and Precision Oncology

REVIEW ARTICLE
Year
: 2018  |  Volume : 1  |  Issue : 2  |  Page : 56--67

Personalized cancer immunotherapy: Today's challenge and tomorrow's promise


Malaka Ameratunga, Wen Xu, Juanita Lopez 
 The Drug Development Unit, Institute of Cancer Research and The Royal Marsden Hospital, Downs Road, Sutton, UK

Correspondence Address:
Dr. Juanita Lopez
Institute of Cancer Research and The Royal Marsden Hospital, Downs Road, Sutton
UK

Precision medicine continues to be the benchmark toward which we strive in cancer research. Conventionally, it is the term applied to the use of genomic information to guide molecularly targeted therapy. However, the advent of clinically effective cancer immunotherapies has posed a challenge for this concept of precision medicine, as robust biomarkers that can differentiate responders from nonresponders have not been described. Here, we review the current scientific efforts using novel technologies to develop biomarkers for immunotherapeutics, to ultimately achieve “personalized immunotherapy.” We first examine the role of programmed death ligand 1 expression and tumor mutational burden, the two most-studied tumoral response biomarkers; and subsequently discuss innovative candidate biomarkers including integrated “omics” approaches utilizing serial tumor, blood, and microbiome sampling. We also detail the challenges in unifying these approaches into a patient-focused immunogram to truly personalize immunotherapy.


How to cite this article:
Ameratunga M, Xu W, Lopez J. Personalized cancer immunotherapy: Today's challenge and tomorrow's promise.J Immunother Precis Oncol 2018;1:56-67


How to cite this URL:
Ameratunga M, Xu W, Lopez J. Personalized cancer immunotherapy: Today's challenge and tomorrow's promise. J Immunother Precis Oncol [serial online] 2018 [cited 2019 Jan 16 ];1:56-67
Available from: http://www.jipoonline.org/article.asp?issn=2590-017X;year=2018;volume=1;issue=2;spage=56;epage=67;aulast=Ameratunga;type=0